Mind Medicine Boasts Current Cash Position Of US$161 Million

Mind Medicine (NEO: MMED) this morning released its fiscal year 2020 financial results. Given that the firm is pre-revenue, the filings are a relative non-event aside from the glimpse it provides into the firms research activities as well as its ability to continue to fund such research.

The fiscal year saw the company use a total cash amount of US$24.2 million, which primarily consisted of research and development expenditures. The company saw total expenses of $32.4 million for the year, of which $15.4 million was related to R&D. $7.7 million meanwhile was spent on general and administrative expenses, and $8.8 million was spent on share based payments.

Other expenses for the year include a listing expense of $2.2 million, while the firm recognized $0.1 million in a foreign exchange gain and a $0.9 million loss on the revaluation of a derivative liability. The firm saw a net loss of $35.1 million for the year as a result.

Looking to the balance sheet, the firm has total current assets of $81.0 million, of which $80.1 million is cash. All liabilities meanwhile amount to just $2.4 million, which consist of accounts payable and accrued liabilities.

The company also indicated this morning that as of March 30, 2021, the firms cash balance currently sits at US$161 million.

Mind Medicine last traded at $3.02 on the NEO.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

When 4% of Global Copper Disappears Overnight | David Gower – Emerita Resources

Mining M&A: Gold X2 Acquires Kesselrun Resources

They Said Oil Was Dead. They Were Wrong. | Michael Judson – Record Resources

Recommended

First Majestic Posts Record Quarterly Silver Production In Q3

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

Related News

MindMed Closes $34.5 Million Financing, Cash Reserves Said To Be At $85 Million

Mind Medicine (NEO: MMED) has completed its previously announced bought deal private placement, raising gross...

Friday, December 11, 2020, 09:15:15 AM

Mind Medicine Sees Co-Founder Become An Activist Shareholder Demanding Changes

An activist shareholder battle might be brewing at Mind Medicine (NEO: MMED). This morning, co-founder...

Thursday, August 11, 2022, 08:41:59 AM

MindMed Begins Study On LSD Neutralizer Technology

MindMed (NEO: MMED) this morning announced that it has begun a study on what it...

Wednesday, February 17, 2021, 08:18:59 AM

Mind Medicine Returns To Trough For Further $25.0 Million

Mind Medicine (NEO: MMED) continues to take investor dollars, this morning announcing a bought deal...

Wednesday, November 25, 2020, 09:25:41 AM

Mind Medicine Announces $10.0 Million Bought Deal At Large Discount To Share Price

Mind Medicine (NEO: MMED) this morning announced a bought deal financing with Eight Capital as...

Tuesday, May 5, 2020, 09:14:31 AM